Autoantibody Signature Differentiates Wilms Tumor Patients from Neuroblastoma PatientsReportar como inadecuado




Autoantibody Signature Differentiates Wilms Tumor Patients from Neuroblastoma Patients - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Several studies report autoantibody signatures in cancer. The majority of these studies analyzed adult tumors and compared the seroreactivity pattern of tumor patients with the pattern in healthy controls. Here, we compared the autoimmune response in patients with neuroblastoma and patients with Wilms tumor representing two different childhood tumors. We were able to differentiate untreated neuroblastoma patients from untreated Wilms tumor patients with an accuracy of 86.8%, a sensitivity of 87.0% and a specificity of 86.7%. The separation of treated neuroblastoma patients from treated Wilms tumor patients- yielded comparable results with an accuracy of 83.8%. We furthermore identified the antigens that contribute most to the differentiation between both tumor types. The analysis of these antigens revealed that neuroblastoma was considerably more immunogenic than Wilms tumor. The reported antigens have not been found to be relevant for comparative analyses between other tumors and controls. In summary, neuroblastoma appears as a highly immunogenic tumor as demonstrated by the extended number of antigens that separate this tumor from Wilms tumor.



Autor: Jana Schmitt , Andreas Keller, Nasenien Nourkami-Tutdibi, Sabrina Heisel, Nunja Habel, Petra Leidinger, Nicole Ludwig, Manfred Ge

Fuente: http://plos.srce.hr/



DESCARGAR PDF




Documentos relacionados